Stay updated with breaking news from Lantern Pharma Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to...
Q1 2024 Earnings Results & Corporate Updates Webcast to be held Thursday, May 9th, 4:30 p.m. ET, register for webcast here, or at the link provided below. ...
HC Wainwright reaffirmed their neutral rating on shares of Lantern Pharma (NASDAQ:LTRN – Free Report) in a research note published on Thursday morning, Benzinga reports. Lantern Pharma Stock Performance Shares of NASDAQ LTRN opened at $5.46 on Thursday. Lantern Pharma has a 12 month low of $2.38 and a 12 month high of $11.99. The […]
Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th with the first webinar on the increasing prevalence of non-small cell lung cancer in...
According to a recent report by Market.us, the Global Drug Repurposing Market size is expected to be worth around USD 51.8 Billion by 2033 from USD 32.1 Billion in 2023, growing at a CAGR of 4.5% during the forecast period from 2024 to 2033.Drug repurposing, also known as drug repositioning or reprofiling, represent...